{
    "clinical_study": {
        "@rank": "77181", 
        "arm_group": {
            "arm_group_label": "N-acetyl-L-cysteine", 
            "arm_group_type": "Experimental", 
            "description": "n-acetyl-l-cysteine 1200 mg BID x 4 weeks"
        }, 
        "brief_summary": {
            "textblock": "This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases\n      pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will\n      be a useful adjunct to opioid treatment in chronic neuropathic pain."
        }, 
        "brief_title": "The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuropathic Pain", 
        "condition_browse": {
            "mesh_term": "Neuralgia"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label study to evaluate the safety and efficacy of N-acetyl-L-cysteine in\n      patients with Chronic neuropathic pain."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18-65 years old\n\n          -  non-cancer neuropathic pain\n\n          -  stable dose of opioids for pain\n\n          -  using breakthrough pain meds\n\n          -  still with persistent pain per VAS\n\n        Exclusion Criteria:\n\n          -  pregnant or nursing\n\n          -  serious medical or psychiatric illness\n\n          -  active stomach ulcer, history or seizures or asthma\n\n          -  breakthrough pain meds other than opioids\n\n          -  using illicit drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840345", 
            "org_study_id": "NAC in Chronic Pain"
        }, 
        "intervention": {
            "arm_group_label": "N-acetyl-L-cysteine", 
            "description": "1200 mg BID x 4 weeks", 
            "intervention_name": "N-acetyl-l-cysteine", 
            "intervention_type": "Drug", 
            "other_name": "NAC"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "uncontrolled", 
            "neuropathic pain"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "pmdillon@vcu.edu", 
                "last_name": "Pamela Dillon, PharmD", 
                "phone": "804-827-1519"
            }, 
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23298"
                }, 
                "name": "Virginia Commonwealth University"
            }, 
            "investigator": {
                "last_name": "Michael F Weaver, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain", 
        "overall_contact": {
            "email": "mfweaver@mcvh-vcu.edu", 
            "last_name": "Michael F Weaver, MD", 
            "phone": "804-827-1519"
        }, 
        "overall_contact_backup": {
            "email": "pmdillon@vcu.edu", 
            "last_name": "Pamela Dillon, PharmD", 
            "phone": "804-827-1519"
        }, 
        "overall_official": {
            "affiliation": "Virginia Commonwealth University", 
            "last_name": "Michael F Weaver, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured in morphine equivalents", 
            "measure": "Opioid use", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840345"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "VAS Pain Quality Assessment Scale Pain Disability Index Pain Catastrophizing Scale", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "PHQ-9", 
                "measure": "Mood", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "PSS", 
                "measure": "Stress", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}